RecruitingNot ApplicableNCT06040905
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
Sponsor
Chung Shan Medical University
Enrollment
100 participants
Start Date
Dec 26, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.
Eligibility
Min Age: 50 YearsMax Age: 80 Years
Inclusion Criteria5
- Clinical diagnosis of mild cognitive impairment (MCI).
- Clinical diagnosis of Alzheimer's Disease.
- MCI and AD patients with hyperglycemia ( Fasting glucose \>=100 mg/dL).
- MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).
- Must be able to swallow tablets.
Exclusion Criteria6
- Cancer patients.
- Severe heart, lung, liver, and kidney diseases.
- Severe disability or aphasia.
- Malnutrition (body weight changes \> 5% within one month).
- Using coenzyme Q10 supplements.
- Warfarin therapy.
Interventions
DIETARY_SUPPLEMENTCoenzyme Q10
300 mg/day (150mg/b.i.d)
OTHERPlacebo
Starch, dextrin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06040905
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location